Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the most common causes of death in AIDS patients. Amphotericin B (AmB) is the corner stone in CM treatment. The effect of AmB was dose-dependent. Recent retrospective study indicated that longer duration rather than higher dose of AmB is necessary to reduce the mortality of CM. We aimed to explore the efficacy and safety of small dose but longer duration of AmB for the treatment of HIV-associated CM.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Number of subjects died at weeks 48
Mortality in intent to treat population
Time frame: 48 weeks after randomization
Number of subjects with CSF culture positive for Cryptococcus at weeks 2
Antifungal Activity
Time frame: 2 weeks after randomization
Number of subjects with disability at weeks 48
Disability rate in intent to treat population
Time frame: 48 weeks after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.